secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062017
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma Q1 net income $56.4M on deferred revenue; clinical trials on track
-----------------------------------------------------------------------------

- Net income $56.4M ($8.46 EPS) vs prior-year net loss $16.6M; revenue $65.3M from Kyowa Kirin termination.
- Cash $82.2M with no debt; operating cash burn $18.5M; funds operations for at least 12 months through data readouts.
- Voruciclib (CDK9) Phase 1 combo with venetoclax dose-escalation data expected early 2024.
- ME-344 (mitochondrial inhibitor) Phase 1b combo with bevacizumab first-cohort data expected H1 2024.
- Abstract on voruciclib monotherapy dose escalation to be presented at ASH Dec 9-12, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000095017023062017/0000950170-23-062017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000095017023062017/meip-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer